文献速递脊柱关节炎

古塞奇尤单抗治疗生物制剂初治活动性银屑病关节炎患者至多2年的3期随机双盲安慰剂对照研究:低影像学进展率与临床疗效相关

Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis.
PubMed 文献 · RMD Open · 2023-01-01

DISCOVER-2研究事后分析评估古塞奇尤单抗治疗活动性银屑病关节炎患者至多2年时影像学进展与临床结局的关系。664例第52周继续治疗的患者纳入分析,达到ACR20/50/70、DAPSA LDA、PASDAS LDA、MDA、VLDA及HAQ-DI≤0.5者在第52周和第100周的vdH-S评分平均变化均小于未达标者。无影像学进展者更可能达到MDA中肿胀/压痛关节计数、患者报告疼痛和总体评估及身体功能正常化等组分。

要点

  • 古塞奇尤单抗Q4W和Q8W组第0至100周vdH-S评分平均变化分别为1.7和1.5。
  • 达到ACR20/50/70、DAPSA LDA、PASDAS LDA、MDA、VLDA及HAQ-DI≤0.5者vdH-S评分变化小于未达标者。
  • 无影像学进展者更可能达到MDA中肿胀/压痛关节计数、疼痛、总体评估及身体功能正常化组分。

核心结论

  • 事后分析中,达到包括MDA在内的低疾病活动度与接受古塞奇尤单抗至多2年患者观察到的影像学进展率降低相关。
  • 影像学无进展者较影像学无应答者更可能达到患者报告的MDA组分:轻微疼痛和身体功能正常化。

研究设计与样本

  • DISCOVER-2为3期、安慰剂对照、随机、双盲研究(NCT03158285)。
  • 纳入生物制剂初治活动性银屑病关节炎成人患者,满足≥5个肿胀关节且≥5个压痛关节,C反应蛋白≥0.6 mg/dL。
  • 患者随机接受古塞奇尤单抗100 mg每4周一次(Q4W)、古塞奇尤单抗100 mg第0周和第4周给药后每8周一次(Q8W)、或安慰剂→古塞奇尤单抗100 mg Q4W(第24周)。
  • 在第0、24、52和100周采用银屑病关节炎改良van der Heijde-Sharp(vdH-S)方法对双手/双足X线片评分。
  • 739例接受治疗患者中664例在第52周继续研究治疗并纳入本分析。

主要发现

  • Q4W组和Q8W组所有患者第0至100周vdH-S评分平均变化分别为1.7和1.5。
  • 所有古塞奇尤单抗随机化患者中,达到ACR20/50/70、DAPSA LDA、PASDAS LDA、MDA、VLDA和HAQ-DI≤0.5者第52周vdH-S评分平均变化为0.2-1.2,未达标者为1.7-4.1。
  • 上述达标者第100周vdH-S评分平均变化为0.3-1.2,未达标者为2.0-4.6。
  • 与有影像学进展(vdH-S总分变化>0.5)者相比,无进展者至第100周更可能达到MDA中与肿胀和压痛关节计数、患者报告疼痛和总体评估及身体功能正常化相关的标准。

关键数值与推荐

  • ACR20/50/70应答采用美国风湿病学会20/50/70应答标准。
  • 低疾病活动度(LDA)定义为DAPSA≤14或PASDAS≤3.2。
  • MDA/VLDA分别为微小疾病活动度/极低疾病活动度。
  • 身体功能正常化定义为HAQ-DI≤0.5。
  • 影像学进展定义为vdH-S总分变化>0.5。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evaluate relationship between radiographic progression and clinical outcomes in post hoc analyses of patients with psoriatic arthritis (PsA) receiving up to 2 years of guselkumab therapy in the phase 3, placebo-controlled, randomised trial, DISCOVER-2. METHODS: Biologic-naïve adults with active PsA (≥5 swollen joints /≥5 tender joints ; C reactive protein ≥0.6 mg/dL) were randomised to guselkumab 100 mg every 4 weeks (Q4W); guselkumab 100 mg at week 0, week 4, then every 8 weeks (Q8W); or placebo→guselkumab 100 mg Q4W (week 24). Radiographs (hands/feet) at week 0, week 24, week 52 and week 100 were scored via PsA-modified van der Heijde-Sharp (vdH-S) methodology. In these post hoc analyses, mean changes in vdH-S scores were summarised according to achievement of American College of Rheumatology 20/50/70 response; low disease activity (LDA) defined by Disease Activity in Psoriatic Arthritis (DAPSA) ≤14 or Psoriatic ArthritiS Disease Activity Score (PASDAS) ≤3.2, or minimal/very low disease activity (MDA/VLDA); and normalised physical function (Health Assessment Questionnaire-Disability Index (HAQ-DI) ≤0.5). Response rates for achieving MDA/VLDA and each component were determined among patients with and without radiographic progression (change in total vdH-S score >0.5). No formal hypothesis testing was performed. RESULTS: 664 of 739 treated patients in DISCOVER-2 continued study treatment at week 52 and were included in these analyses. Mean changes in vdH-S scores from weeks 0 to 100 among all patients in the Q4W and Q8W groups were 1.7 and 1.5, respectively. Among all guselkumab-randomised patients, those who achieved ACR20/50/70, DAPSA LDA, PASDAS LDA, MDA, VLDA and HAQ-DI ≤0.5 (normalised physical function) had smaller mean changes in vdH-S scores than did non-responders at week 52 (0.2-1.2 vs 1.7-4.1) and week 100 (0.3-1.2 vs 2.0-4.6). Relative to patients with radiographic progression, those without progression were more likely to achieve the MDA criteria related to swollen and tender joint counts, patient-reported pain and global assessment, and normalised physical function through week 100. CONCLUSION: In these post hoc analyses, the achievement of low levels of disease activity, including MDA, was associated with diminished rates of radiographic progression observed in patients receiving up to 2 years of guselkumab. Radiographic non-progressors were more likely to achieve patient-reported MDA criteria of minimal pain and normalised physical function compared with radiographic non-responders. TRIAL REGISTRATION NUMBER: NCT03158285.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Gottlieb AB, McInnes IB, Rahman P, et al. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. RMD Open. 2023. PMID: 36828643. doi:10.1136/rmdopen-2022-002789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。